Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × nintedanib × CNS × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Gastrointestinal 2 Dermatologic 1 CNS 1

Conditions

Interventions

Temozolomide 100 Radiotherapy 47 Bevacizumab 33 Carboplatin 23 Irinotecan 20 pembrolizumab 17 Radiosurgery 16 Nivolumab 16 Radiation 14 Cyclophosphamide 11 Magnetic Resonance Spectroscopy 10 fludarabine 8 Trastuzumab 8 Radiotherapy, Intensity-Modulated 8 Carmustine 8 Surgical Procedures, Operative 7 Specimen Handling 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Everolimus 7 Erlotinib Hydrochloride 7 temsirolimus 6 Vorinostat 6 Radiotherapy, Conformal 6 Lomustine 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Gemcitabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01666600 2017-11-01

NOA-12: BIBF1120 and R-RT in Glioblastoma

University Hospital Heidelberg

Phase 1/2 Terminated

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡